Evaluating the repurposing potential of the anti‐depressant Agomelatine for Alzheimer’s Disease

Agomelatine showed a female only reduction in cognitive deficits, which did not correlate with a decrease in amyloid beta plaque deposition. This finding paired with the decrease of DDIT3 gene expression suggests that Agomelatine has a neuroprotective mechanism that is independent of amyloid burden. Future studies will analyze neuronal loss via NeuN staining to determine if AGO prevents neuronal loss, thus supporting its ability to mitigate cognitive deficits in the TgF344-AD rat model.